 WALTHAM, Mass., Jan. 26, 2021 GLOBE NEWSWIRE -- Entasis Therapeutics Holdings Inc. NASDAQ: ETTX, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program EAP for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter baumannii infections, including carbapenem and multidrug resistant strains. 